WO2015020993A3 - RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA - Google Patents
RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA Download PDFInfo
- Publication number
- WO2015020993A3 WO2015020993A3 PCT/US2014/049677 US2014049677W WO2015020993A3 WO 2015020993 A3 WO2015020993 A3 WO 2015020993A3 US 2014049677 W US2014049677 W US 2014049677W WO 2015020993 A3 WO2015020993 A3 WO 2015020993A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ataxia
- methods
- friedreich
- treatment
- rnai compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
- C12N2310/533—Physical structure partially self-complementary or closed having a mismatch or nick in at least one of the strands
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides ribonucleic acid (RNA) molecules, such as siRNA and shRNA molecules, that compensate for a frataxin deficiency or mutation, expression vectors encoding the same, and methods of using the same (e.g., to treat Friedreich's ataxia).
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361862254P | 2013-08-05 | 2013-08-05 | |
US61/862,254 | 2013-08-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2015020993A2 WO2015020993A2 (en) | 2015-02-12 |
WO2015020993A3 true WO2015020993A3 (en) | 2015-11-05 |
Family
ID=52462029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/049677 WO2015020993A2 (en) | 2013-08-05 | 2014-08-05 | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2015020993A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9163231B2 (en) | 2006-03-07 | 2015-10-20 | The Trustees Of The University Of Pennsylvania | Random RNAi libraries, methods of generating same, and screening methods utilizing same |
WO2015023941A1 (en) | 2013-08-16 | 2015-02-19 | Rana Therapeutics, Inc. | Oligonucleotides targeting euchromatin regions of genes |
EP3256591A4 (en) | 2015-02-13 | 2018-08-08 | Translate Bio Ma, Inc. | Hybrid oligonucleotides and uses thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070116691A1 (en) * | 2005-10-18 | 2007-05-24 | National Jewish Medical And Research Center | Conditionally immortalized long-term stem cells and methods of making and using such cells |
US20120308645A1 (en) * | 2002-11-01 | 2012-12-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
US20130096183A1 (en) * | 2010-06-23 | 2013-04-18 | Curna, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
-
2014
- 2014-08-05 WO PCT/US2014/049677 patent/WO2015020993A2/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120308645A1 (en) * | 2002-11-01 | 2012-12-06 | The Trustees Of The University Of Pennsylvania | Compositions and methods for sirna inhibition of hif-1 alpha |
US20070116691A1 (en) * | 2005-10-18 | 2007-05-24 | National Jewish Medical And Research Center | Conditionally immortalized long-term stem cells and methods of making and using such cells |
US20130096183A1 (en) * | 2010-06-23 | 2013-04-18 | Curna, Inc. | Treatment of sodium channel, voltage-gated, alpha subunit (scna) related diseases by inhibition of natural antisense transcript to scna |
Non-Patent Citations (1)
Title |
---|
"CW908201, RPCI42_148G4.TJ RPCI-42 Bos taurus genomic clone RPCI42_148G4, genomic survey sequence", 8 December 2004 (2004-12-08), Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/nucgss/CW908201> [retrieved on 20150225] * |
Also Published As
Publication number | Publication date |
---|---|
WO2015020993A2 (en) | 2015-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202110854B (en) | Tmprss6 irna compositions and methods of use thereof | |
MX2018006989A (en) | Methods and compositions for treating a serpinc1-associated disorder. | |
PH12017500669A1 (en) | Compositions and methods for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression | |
MX2021009118A (en) | Compositions and methods for inhibiting expression of the alas1 gene. | |
MX2019008380A (en) | Complement component c5 irna compositions and methods of use thereof. | |
MX2015008697A (en) | Age-related macular degeneration treatment. | |
PH12014501106B1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
MX2018013216A (en) | Compositions and methods for inhibiting expression of tmprss6 gene. | |
MX2019006413A (en) | Serpinc1 irna compositions and methods of use thereof. | |
MX2021000656A (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF. | |
MX2021010716A (en) | Compositions and methods for inhibiting expression of the lect2 gene. | |
MX2022001017A (en) | Compositions and methods for inhibiting expression of the alas1 gene. | |
WO2014093746A3 (en) | Methods and compositions for the specific inhibition of ckap5 by double-stranded rna | |
WO2015020993A3 (en) | RNAi COMPOSITIONS AND METHODS FOR TREATMENT OF FRIEDREICH'S ATAXIA | |
MX2019007110A (en) | Reagents for treatment of oculopharyngeal muscular dystrophy (opmd) and use thereof. | |
MX368084B (en) | Sirna and their use in methods and compositions for the treatment and/or prevention of eye conditions. | |
TW202423457A (en) | Methods and compositions for treating a serpinc1-associated disorder | |
TN2014000211A1 (en) | Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases | |
MY185464A (en) | Complement component c5 irna compositions and methods of use thereof | |
EA037110B9 (en) | PCSK9 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14835398 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14835398 Country of ref document: EP Kind code of ref document: A2 |